Figure S1. Relative risks and 95% confidence intervals for risk of adverse clinical events associated with quintile of facility-level proportions of patients with at least two of three CKD-MBD biomarkers out of or above target ranges, using a PTH target range of 150-300 pg/mL.
Quintiles of facility level proportions of CKD-MBD composite score were based on proportions of patients within each facility who were out of target or above target. “Out of target” was characterized by at least two CKD-MBD laboratory values above or below defined target ranges for PTH, calcium, and phosphate. “Above target” was characterized by at least two CKD-MBD laboratory parameters above defined target ranges for PTH, calcium, and phosphate. Target ranges for CKD-MBD laboratory parameters were 150-300 pg/mL for PTH, 8.4-10.2 mg/dL for calcium, and 3.5-5.5 mg/dL for phosphate. Analyses were adjusted for baseline patient demographics, dialysis duration, previous hospitalization, body mass index, comorbid conditions, facility size, and geography. CKD-MBD, chronic kidney disease-mineral bone disorder; CV, cardiovascular; CI confidence interval; PTH, parathyroid hormone.